Takeda receives positive chmp opinion for recombinant adamts13 (radamts13) in congenital thrombotic thrombocytopenic purpura (cttp)

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that the european medicines agency's (ema) committee for medicinal products for human use (chmp) has recommended the approval, under exceptional circumstances, of recombinant adamts13 (radamts13) for the treatment of adamts13 deficiency in children and adult patients with cttp. the european commission (ec) will consider the chmp positive opinion when determining the potential marketing authorization for.
TAK Ratings Summary
TAK Quant Ranking